ES2149338T3 - Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica. - Google Patents

Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.

Info

Publication number
ES2149338T3
ES2149338T3 ES95900491T ES95900491T ES2149338T3 ES 2149338 T3 ES2149338 T3 ES 2149338T3 ES 95900491 T ES95900491 T ES 95900491T ES 95900491 T ES95900491 T ES 95900491T ES 2149338 T3 ES2149338 T3 ES 2149338T3
Authority
ES
Spain
Prior art keywords
nitric oxide
injuries
compounds
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900491T
Other languages
English (en)
Inventor
David A Wink Jr
James B Mitchell
Angelo Russo
Murali C Krishna
Ingeborg Hanbauer
Matthew B Grisham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
US Department of Health and Human Services
Original Assignee
Louisiana State University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University, US Department of Health and Human Services filed Critical Louisiana State University
Application granted granted Critical
Publication of ES2149338T3 publication Critical patent/ES2149338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SUMINISTRA UN METODO PARA TRATAR LOS DAÑOS DEL TEJIDO INDUCIDOS POR RADICALES LIBRES DEL OXIGENO ASOCIADOS CON LESIONES DE REPERFUSION DE ISQUEMIA, EN EL QUE EL OXIDO NITRICO SE LIBERA HACIA LAS CELULAS/TEJIDO DE OBJETIVO A TRAVES DE LA ADMINISTRACION DE UN COMPUESTO QUE CONTIENE OXIDO NITRICO QUE ESPONTANEAMENTE LIBERA EL OXIDO NITRICO BAJO CONDICIONES FISIOLOGICAS SIN REQUERIR LA PRESENCIA DE OXIGENO.
ES95900491T 1993-11-02 1994-10-31 Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica. Expired - Lifetime ES2149338T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14661093A 1993-11-02 1993-11-02
PCT/US1994/012510 WO1995012394A1 (en) 1993-11-02 1994-10-31 Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury

Publications (1)

Publication Number Publication Date
ES2149338T3 true ES2149338T3 (es) 2000-11-01

Family

ID=22518169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900491T Expired - Lifetime ES2149338T3 (es) 1993-11-02 1994-10-31 Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.

Country Status (12)

Country Link
US (1) US5789447A (es)
EP (1) EP0726768B1 (es)
JP (1) JPH09508097A (es)
AT (1) ATE192922T1 (es)
AU (1) AU704173B2 (es)
CA (1) CA2175467A1 (es)
DE (1) DE69424560T2 (es)
DK (1) DK0726768T3 (es)
ES (1) ES2149338T3 (es)
GR (1) GR3034099T3 (es)
PT (1) PT726768E (es)
WO (1) WO1995012394A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US6190704B1 (en) * 1994-09-23 2001-02-20 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Regulation of wound healing by nitric oxide
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
DE69736230T2 (de) * 1996-04-05 2007-05-31 The General Hospital Corp., Boston Behandlung einer hämoglobinstörung
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
JP2001527072A (ja) 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
ES2147162B1 (es) 1999-01-27 2001-03-16 Lacer Sa "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
CN101310772B (zh) * 1999-06-14 2012-02-08 亨利福特保健系统公司 用于诱导神经发生的氧化氮供体
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
WO2001065935A1 (en) * 2000-03-08 2001-09-13 Yoram Vodovotz Kidney perfusion solution containing nitric oxide donor
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
FR2812200B1 (fr) * 2000-07-27 2003-01-03 Oxykines Therapeutics Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote ; et utilisations
AU8484901A (en) * 2000-08-11 2002-02-25 David R Whitlock Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
WO2003026717A1 (en) * 2001-09-26 2003-04-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US20050244382A9 (en) * 2002-01-11 2005-11-03 Whitlock David R Compositions including ammonia oxidizing bacteria and methods of using same
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
WO2004017939A1 (ja) * 2002-08-20 2004-03-04 Terumo Kabushiki Kaisha 体内埋込医療器具
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
US20050009789A1 (en) * 2003-05-13 2005-01-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service Cyclooxygenase inhibition with nitroxyl
EP1653978B1 (en) 2003-07-09 2020-06-03 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of nitrite salts for the treatment of cardiovascular conditions
EP1667646A4 (en) * 2003-09-26 2007-07-04 David R Whitlock METHOD FOR USE OF AMMONIA-OXIDATING BACTERIA
US20080085329A1 (en) * 2003-10-22 2008-04-10 Fred Hutchinson Cancer Research Center, Inc. Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
JP2007523900A (ja) 2004-02-09 2007-08-23 ノクシライザー，インコーポレイテッド 一酸化窒素放出分子
US20070232996A1 (en) * 2004-04-29 2007-10-04 Cube Medical A/S Balloon for Use in Angioplasty with an Outer Layer of Nanofibers
US20080029093A1 (en) * 2004-05-11 2008-02-07 Alex Stenzler Intermittent Dosing Of Nitric Oxide Gas
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
CA2605631A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
US8557300B2 (en) * 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
WO2007002444A1 (en) * 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
WO2007057763A2 (en) * 2005-11-18 2007-05-24 Pulmonox Technologies Corporation Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
CA2632683A1 (en) * 2005-12-06 2007-06-14 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
AU2014201936B2 (en) * 2006-10-06 2016-07-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
EP3424950A1 (en) * 2006-10-06 2019-01-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
EP1939179A1 (en) 2006-12-28 2008-07-02 Lacer, S.A. Stable S-nitrosothiols, method of synthesis and use
WO2008089282A2 (en) * 2007-01-16 2008-07-24 Silver James H Sensors for detecting subtances indicative of stroke, ischemia, infection or inflammation
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
WO2008134740A1 (en) * 2007-04-30 2008-11-06 The Trustees Of The University Of Pennsylvania System and method of resuscitation of a mammal
AU2008345034A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
BR112012003792B1 (pt) 2009-08-21 2020-05-19 Novan Inc composição tópica, e, uso da composição tópica
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN105919987B (zh) * 2009-12-07 2020-04-03 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物及其用途
MX356796B (es) * 2009-12-07 2018-06-14 Cardioxyl Pharmaceuticals Inc Derivados de hidroxilamina bis-acilados.
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
WO2012154975A2 (en) * 2011-05-11 2012-11-15 Stc.Unm Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
KR20230165365A (ko) 2014-04-15 2023-12-05 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
US10662063B1 (en) * 2016-06-06 2020-05-26 University Of Puerto Rico Photosensitized release of nitric oxide
CN109937234B (zh) 2016-10-07 2021-11-26 北卡罗来纳大学教堂山分校 S-亚硝基硫醇介导的超支化聚酯
EP3565848A4 (en) 2017-01-03 2020-09-02 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING ALGINATES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
WO2018178902A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
CA3082130A1 (en) 2017-11-15 2019-05-23 The University Of North Carolina At Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
CN111836648A (zh) 2018-03-06 2020-10-27 北卡罗来纳大学查佩尔希尔分校 作为可生物降解抗菌支架的一氧化氮释放型环糊精以及其相关方法
AU2019414421B2 (en) 2018-12-28 2023-08-31 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153094A (en) * 1959-06-10 1964-10-13 Du Pont Nitrosamine manufacture
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs

Also Published As

Publication number Publication date
DE69424560T2 (de) 2001-01-18
GR3034099T3 (en) 2000-11-30
JPH09508097A (ja) 1997-08-19
US5789447A (en) 1998-08-04
ATE192922T1 (de) 2000-06-15
AU704173B2 (en) 1999-04-15
PT726768E (pt) 2000-11-30
EP0726768A1 (en) 1996-08-21
DE69424560D1 (de) 2000-06-21
EP0726768B1 (en) 2000-05-17
WO1995012394A1 (en) 1995-05-11
CA2175467A1 (en) 1995-05-11
AU8130094A (en) 1995-05-23
DK0726768T3 (da) 2000-10-02

Similar Documents

Publication Publication Date Title
ES2149338T3 (es) Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.
CY1108882T1 (el) Φαρμακευτικο μεσο για την αγωγη ιικων δερματικων και νεοπλασιακων παθησεων
NL300382I1 (nl) Treatment of pompe&#39;s disease
ES2071725T3 (es) Diesteres fosfato de acido ascorbico y tocoferilo para la inhibicion de la reaccion de maillard.
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ES2042528T3 (es) Un procedimiento de preparacion de una composicion para potenciar la penetracion por membranas de al menos un agente sistematicamente activo.
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
DK0690851T3 (da) Guanidin-derivater, som er anvendelige til behandling
BR9914385A (pt) Composição útil para o tratamento e prevenção de infecções protozoárias no homem e em animais, e, método de tratamento de uma infecção protozoária no homem e em animais
DK127788A (da) Farmaceutiske praeparater til anvendelse til behandling eller forebyggelse af sygdomme i mavetarmkanalen
ES2096577T3 (es) Utilizacion del cetoconazol y un retinoide para el tratamiento del acne vulgar.
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
MY104521A (en) Treatment of depression.
KR900701278A (ko) 바이러스 감염 치료용 담즙산
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.
ZA962635B (en) Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
AR026242A1 (es) Empleo de 2-amino-3,4-dihidro-quinazolinas para la preparacion de un medicamento para el tratamiento o profilaxis de enfermedades provocadas por estadosisquemicos
AR011115A1 (es) Compuestos sustituidos con sulfonamida, empleos para la preparacion de un medicamento y agente curativo
Czernielewski et al. Oral treatment of acne vulgaris and oil acne with tetracycline
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 726768

Country of ref document: ES